Verastem Prices $250 Million Share Sale At $8.00, Above Last Sale, To Fund KRAS Drug

The $8.00 price tops Tuesday's $7.45 last sale, and the new shares equal 25.5% of the count outstanding after the offering.

Share
Verastem Prices $250 Million Share Sale At $8.00, Above Last Sale, To Fund KRAS Drug

Verastem priced an offering of 30,937,500 common shares at $8.00 each, or $250.0 million in gross proceeds, according to a prospectus supplement dated Wednesday. The company said the money is earmarked for its KRAS G12D drug candidate VS-7375 and general corporate purposes.

The terms

The $8.00 price is above the $7.45 last reported sale on October 13, so the deal carries a premium to that close rather than a discount. Verastem is also offering pre-funded warrants (warrants with a nominal exercise price) for up to 312,503 shares, at $7.9999 each, to certain investors in place of common stock.

After the offering, 121,419,115 shares will be outstanding, assuming no pre-funded warrants are exercised. The 30,937,500 new shares equal 25.5% of that count. The filing's base was 90,481,615 shares outstanding as of June 30, 2026.

Underwriting discounts come to $0.48 a share, leaving proceeds to Verastem of $234,999,991.31 before expenses. Jefferies, Guggenheim Securities and Cantor are joint book-running managers.

The company said it will use net proceeds "to fund the continued clinical development of VS-7375, and for working capital and other general corporate purposes." It also warned that management will keep broad discretion over how the money is spent.

What else the filing carries

Verastem suspended and terminated its at-the-market sales prospectus with Cantor Fitzgerald in connection with the deal, and said no shares had been sold under it. The sales agreement itself stays in force.

The filing gives preliminary third-quarter net product revenue of $23.9 million to $24.1 million, versus $11.2 million a year earlier. Cash, cash equivalents and investments were an estimated $172.8 million at September 30, 2026, against $137.7 million a year before. These figures are unaudited and subject to revision.

CEO Daniel Paterson notified the board on October 12 that he will retire as president and CEO effective January 1, 2027, and stay on as a director. Michael Bailey will succeed him.

The filing also reports that the FDA accepted the company's Blister Pack new drug application on October 7 and granted priority review. New VS-7375 data from its ongoing trial included a 41% confirmed response rate in second-or-later-line pancreatic cancer at the 900 mg dose.

What to watch

Delivery of the securities is expected on or about October 15, 2026. The company and its executive officers and directors are bound by 60-day lock-up agreements, with specified exceptions. The shares sold in the offering are not locked up.

In Wednesday after-hours trading, Verastem shares were at $7.92, up 2.72% from the $7.71 regular close, an indicative reading in lighter volume.

Full third-quarter results will arrive in the company's quarterly report on Form 10-Q, which will show how far the preliminary revenue range holds.

Sources

More on Verastem

All Verastem (VSTM) coverage →